Cadence Pharmaceuticals, Inc. · San Diego, CA United States ·(NASDAQ (GM): CADX)

Cadence Pharmaceuticals follows the rhythm of hospitals' medical needs. The biopharmaceutical company develops drug candidates primarily for use in a hospital setting. The company licenses rights to compounds and develops them for sale in untapped markets or for new indications. Cadence's late-stage candidates include Acetavance (injectable acetaminophen), which is marketed in Europe by the Bristol-Myers Squibb Company under the name Perfalgan, for treating acute pain and fever. The company also is developing Omigard, a topical antimicrobial gel used to prevent and treat infections in surgical wounds, burns, and medical device-related wounds such as from catheters. To read the full description, subscribe now.